KR20190129923A - 듀테로화된 이미다조[4,5-c]퀴놀린-2-온 화합물 및 암 치료시 이들의 용도 - Google Patents
듀테로화된 이미다조[4,5-c]퀴놀린-2-온 화합물 및 암 치료시 이들의 용도 Download PDFInfo
- Publication number
- KR20190129923A KR20190129923A KR1020197030079A KR20197030079A KR20190129923A KR 20190129923 A KR20190129923 A KR 20190129923A KR 1020197030079 A KR1020197030079 A KR 1020197030079A KR 20197030079 A KR20197030079 A KR 20197030079A KR 20190129923 A KR20190129923 A KR 20190129923A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- formula
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472080P | 2017-03-16 | 2017-03-16 | |
| US62/472,080 | 2017-03-16 | ||
| PCT/EP2018/056516 WO2018167203A1 (en) | 2017-03-16 | 2018-03-15 | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190129923A true KR20190129923A (ko) | 2019-11-20 |
Family
ID=61801891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197030079A Abandoned KR20190129923A (ko) | 2017-03-16 | 2018-03-15 | 듀테로화된 이미다조[4,5-c]퀴놀린-2-온 화합물 및 암 치료시 이들의 용도 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20200087300A1 (enExample) |
| EP (1) | EP3596076A1 (enExample) |
| JP (1) | JP2020514344A (enExample) |
| KR (1) | KR20190129923A (enExample) |
| CN (1) | CN110431139B (enExample) |
| AU (1) | AU2018234985B2 (enExample) |
| BR (1) | BR112019018723A2 (enExample) |
| CA (1) | CA3055258A1 (enExample) |
| CL (1) | CL2019002527A1 (enExample) |
| CO (1) | CO2019010029A2 (enExample) |
| CR (1) | CR20190429A (enExample) |
| DO (1) | DOP2019000228A (enExample) |
| EA (1) | EA038233B1 (enExample) |
| EC (1) | ECSP19066134A (enExample) |
| IL (1) | IL269272A (enExample) |
| JO (1) | JOP20190209A1 (enExample) |
| MA (1) | MA49884A (enExample) |
| MX (1) | MX2019010898A (enExample) |
| NI (1) | NI201900094A (enExample) |
| PE (1) | PE20191486A1 (enExample) |
| PH (1) | PH12019502086A1 (enExample) |
| SG (1) | SG11201908065YA (enExample) |
| TW (1) | TW201843151A (enExample) |
| UA (1) | UA124554C2 (enExample) |
| WO (1) | WO2018167203A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LV15575A (lv) * | 2019-12-20 | 2021-06-20 | Latvijas Organiskās Sintēzes Institūts | Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana |
| CN116194109A (zh) | 2020-06-24 | 2023-05-30 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和atm抑制剂的组合 |
| CN116056698B (zh) * | 2020-09-21 | 2024-11-19 | 威尚（上海）生物医药有限公司 | 具有血脑屏障穿透能力的取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮化合物 |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| WO2022128833A1 (en) | 2020-12-15 | 2022-06-23 | Merck Patent Gmbh | Solid transition metal-ligand complexes |
| CN118434736A (zh) * | 2022-01-26 | 2024-08-02 | 正大天晴药业集团股份有限公司 | 含有肼基的化合物 |
| WO2026120558A1 (en) | 2024-12-06 | 2026-06-11 | Sun Pharma Advanced Research Company Limited | Macrocyclic compounds as atm inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US20090082387A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched nvp-bez234 |
| MA33332B1 (fr) * | 2009-06-04 | 2012-06-01 | Novartis Ag | Dérivés de la 1h-imidazo[4,5-c]quinolinone |
| CN102372711B (zh) * | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
| CN102399218A (zh) | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| NO2714752T3 (enExample) * | 2014-05-08 | 2018-04-21 | ||
| PL3277681T3 (pl) * | 2015-04-02 | 2019-10-31 | Merck Patent Gmbh | Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm |
| GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
-
2017
- 2017-06-16 JO JOP/2019/0209A patent/JOP20190209A1/ar unknown
-
2018
- 2018-03-15 KR KR1020197030079A patent/KR20190129923A/ko not_active Abandoned
- 2018-03-15 MX MX2019010898A patent/MX2019010898A/es unknown
- 2018-03-15 TW TW107108833A patent/TW201843151A/zh unknown
- 2018-03-15 SG SG11201908065YA patent/SG11201908065YA/en unknown
- 2018-03-15 WO PCT/EP2018/056516 patent/WO2018167203A1/en not_active Ceased
- 2018-03-15 CR CR20190429A patent/CR20190429A/es unknown
- 2018-03-15 CN CN201880017916.4A patent/CN110431139B/zh active Active
- 2018-03-15 BR BR112019018723A patent/BR112019018723A2/pt not_active Application Discontinuation
- 2018-03-15 UA UAA201910213A patent/UA124554C2/uk unknown
- 2018-03-15 EA EA201992090A patent/EA038233B1/ru unknown
- 2018-03-15 MA MA049884A patent/MA49884A/fr unknown
- 2018-03-15 US US16/493,850 patent/US20200087300A1/en not_active Abandoned
- 2018-03-15 CA CA3055258A patent/CA3055258A1/en not_active Abandoned
- 2018-03-15 JP JP2019549446A patent/JP2020514344A/ja not_active Ceased
- 2018-03-15 AU AU2018234985A patent/AU2018234985B2/en not_active Ceased
- 2018-03-15 EP EP18713818.5A patent/EP3596076A1/en not_active Withdrawn
- 2018-03-15 PE PE2019001872A patent/PE20191486A1/es unknown
-
2019
- 2019-09-03 CL CL2019002527A patent/CL2019002527A1/es unknown
- 2019-09-06 DO DO2019000228A patent/DOP2019000228A/es unknown
- 2019-09-11 IL IL26927219A patent/IL269272A/en unknown
- 2019-09-12 EC ECSENADI201966134A patent/ECSP19066134A/es unknown
- 2019-09-13 NI NI201900094A patent/NI201900094A/es unknown
- 2019-09-13 PH PH12019502086A patent/PH12019502086A1/en unknown
- 2019-09-16 CO CONC2019/0010029A patent/CO2019010029A2/es unknown
-
2021
- 2021-07-20 US US17/380,323 patent/US20210347775A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP19066134A (es) | 2019-09-30 |
| AU2018234985A1 (en) | 2019-10-24 |
| CA3055258A1 (en) | 2018-09-20 |
| CN110431139A (zh) | 2019-11-08 |
| CL2019002527A1 (es) | 2019-11-22 |
| SG11201908065YA (en) | 2019-09-27 |
| EA201992090A1 (ru) | 2020-03-06 |
| EA038233B1 (ru) | 2021-07-28 |
| CO2019010029A2 (es) | 2019-09-30 |
| US20200087300A1 (en) | 2020-03-19 |
| WO2018167203A1 (en) | 2018-09-20 |
| TW201843151A (zh) | 2018-12-16 |
| PH12019502086A1 (en) | 2020-03-09 |
| PE20191486A1 (es) | 2019-10-18 |
| UA124554C2 (uk) | 2021-10-05 |
| AU2018234985B2 (en) | 2020-04-02 |
| CN110431139B (zh) | 2022-07-05 |
| CR20190429A (es) | 2019-11-12 |
| EP3596076A1 (en) | 2020-01-22 |
| MX2019010898A (es) | 2019-11-07 |
| BR112019018723A2 (pt) | 2020-04-07 |
| JOP20190209A1 (ar) | 2019-09-12 |
| IL269272A (en) | 2019-11-28 |
| NI201900094A (es) | 2020-03-18 |
| MA49884A (fr) | 2020-06-24 |
| US20210347775A1 (en) | 2021-11-11 |
| JP2020514344A (ja) | 2020-05-21 |
| DOP2019000228A (es) | 2019-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11613539B2 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| EP3140303B1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| CN110431139B (zh) | 氘代的咪唑并[4,5-c]喹啉-2-酮化合物及其在治疗癌症中的用途 | |
| JP2018531226A6 (ja) | 癌の治療のための血管拡張性失調症変異（ａｔｍ）キナーゼの選択的モジュレーターとしての８−［６−［３−（アミノ）プロポキシ］−３−ピリジル］−１−イソプロピル−イミダゾ［４，５−ｃ］キノリン−２−オン誘導体 | |
| KR20180070703A (ko) | 이미다조[4,5-c]퀴놀린-2-온 화합물 및 암 치료에서의 이의 용도 | |
| TW201805284A (zh) | 咪唑并［4，5－c］喹啉－2酮化合物及其治療癌症之用途 | |
| TW201808948A (zh) | 咪唑并[4,5-c]喹啉-2-酮化合物以及它們在治療癌症中之用途 | |
| JP2019513730A (ja) | 癌を治療するためのＡＴＭ（毛細血管拡張性運動失調症変異）キナーゼモジュレータとしてのＮ，Ｎ−ジメチル−３−［［５−（３−メチル−２−オキソ−１−テトラヒドロピラン−４−イル−イミダゾ［４，５−ｃ］キノリン−８−イル）−２−ピリジル］オキシ］プロパン−１−アミンオキシド | |
| HK40016607A (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| HK1257413B (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| HK1232528A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| HK1232528B (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PC1904 | Unpaid initial registration fee |
St.27 status event code: A-2-2-U10-U14-oth-PC1904 St.27 status event code: N-2-6-B10-B12-nap-PC1904 |